NCT07385079 2026-02-03
Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Not yet recruiting
Clinical Trials
13 trialsNCT07373990 2026-01-28
Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT05587374 2025-01-23
GEMSTONE
Sun Yat-sen University
Phase 3 Active not recruiting
NCT03840421 2025-01-13
GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Active not recruiting
NCT03427827 2024-04-09
DIPPER
Sun Yat-sen University
Phase 3 Active not recruiting
NCT05564286 2024-02-06
Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer
Shantou University Medical College
Phase 3 Completed
NCT03837808 2022-11-07
Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Unknown
NCT00370890 2022-02-17
A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy
Chinese University of Hong Kong
Phase 3 Completed
NCT01528618 2021-10-04
Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Completed
NCT04453826 2020-09-28
Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Recruiting
NCT02137096 2019-06-24
Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma
University of Florida
Phase 3 Terminated
NCT00828386 2019-01-18
NPC2006
Groupe Oncologie Radiotherapie Tete et Cou
Phase 3 Terminated
NCT01074021 2015-10-30
Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer
Biotech Pharmaceutical Co., Ltd.
Phase 3 Unknown